Literature DB >> 1548061

Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

S Xu1, R D Arbeit, J C Lee.   

Abstract

Phagocytosis by human polymorphonuclear leukocytes (PMNs) is an important host defense against infections caused by Staphylococcus aureus. Using an in vitro assay, we compared the opsonic requirements for phagocytic killing of prototype strains of encapsulated (type 1) and microencapsulated (type 5 and type 8) S. aureus by human PMNs. More than 85% of broth-grown, logarithmic-phase type 5 and 8 S. aureus organisms were killed by PMNs incubated with fresh normal human, rabbit, or guinea pig serum with complement activity. Under similar conditions, the highly encapsulated type 1 strain was not killed. Both encapsulated and microencapsulated strains were opsonized for phagocytosis by heat-inactivated serum raised in rabbits to killed bacteria. Opsonization by homologous serum was required for phagocytosis of the type 1 strain. In contrast, microencapsulated type 5 and 8 S. aureus organisms were killed by heat-inactivated rabbit serum raised to type 5, type 8, or nonencapsulated isolates; this result suggested that antibodies to the capsule or to cell wall components other than the capsule could opsonize these organisms for phagocytosis. The specificity of the assay was confirmed with capsule type 5-specific monoclonal antibodies, which were opsonic only for the type 5 S. aureus isolate. These studies indicate that, unlike the highly encapsulated type 1 strain, broth-grown microencapsulated S. aureus strains do not resist opsonophagocytic killing in vitro by normal serum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548061      PMCID: PMC257004          DOI: 10.1128/iai.60.4.1358-1362.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Capsule production and virulence among strains of Staphylococcus aureus.

Authors:  B B Wiley; N H Maverakis
Journal:  Ann N Y Acad Sci       Date:  1974-07-31       Impact factor: 5.691

2.  Structural analysis of the cellular constituents of a fresh clinical isolate of Staphylococcus aureus, and their role in the interaction between the organisms and polymorphonuclear leukocytes in the presence of serum factors.

Authors:  W W Karakawa; D A Young; J A Kane
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

3.  Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.

Authors:  A Albus; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

4.  Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits.

Authors:  D P Greenberg; J I Ward; A S Bayer
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

5.  Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes.

Authors:  P K Peterson; B J Wilkinson; Y Kim; D Schmeling; P G Quie
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

6.  Cryptic peptidoglycan and the antiphagocytic effect of the Staphylococcus aureus capsule: model for the antiphagocytic effect of bacterial cell surface polymers.

Authors:  B J Wilkinson; P K Peterson; P G Quie
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

7.  Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis.

Authors:  B J Wilkinson; S P Sisson; Y Kim; P K Peterson
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

8.  Diagnosing Staphylococcus aureus endocarditis by detecting antibodies against S. aureus capsular polysaccharide types 5 and 8.

Authors:  B Christensson; A Boutonnier; U Ryding; J M Fournier
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

9.  Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.

Authors:  A Fattom; R Schneerson; S C Szu; W F Vann; J Shiloach; W W Karakawa; J B Robbins
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.609

10.  Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse.

Authors:  Z A COHN
Journal:  Yale J Biol Med       Date:  1962-08
View more
  29 in total

1.  Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus.

Authors:  S Ouyang; S Sau; C Y Lee
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

2.  Bacteriophage Resistance Alters Antibiotic-Mediated Intestinal Expansion of Enterococci.

Authors:  Anushila Chatterjee; Cydney N Johnson; Phat Luong; Karthik Hullahalli; Sara W McBride; Alyxandria M Schubert; Kelli L Palmer; Paul E Carlson; Breck A Duerkop
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis.

Authors:  I M Nilsson; J C Lee; T Bremell; C Rydén; A Tarkowski
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats.

Authors:  J C Lee; J S Park; S E Shepherd; V Carey; A Fattom
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Staphylococcus aureus infection after splenectomy and splenic autotransplantation in BALB/c mice.

Authors:  F M Teixeira; B F Fernandes; A B Rezende; R R P Machado; C C S Alves; S M Perobelli; S I Nunes; R E Farias; M F Rodrigues; A P Ferreira; S C Oliveira; H C Teixeira
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

6.  Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains.

Authors:  B Poutrel; F B Gilbert; M Lebrun
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

7.  Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureus.

Authors:  S Sau; J Sun; C Y Lee
Journal:  J Bacteriol       Date:  1997-03       Impact factor: 3.490

8.  Survey of potential factors involved in the low frequency of CP5 and CP8 expression in Staphylococcus aureus isolates from mastitis of dairy cattle from Argentina, Chile, and Uruguay.

Authors:  Maria Belen Ambroggio; Melina Soledad Perrig; Cecilia Camussone; Nazarena Pujato; Alicia Bertón; Edgardo Gianneechini; Silvia Alvarez; Ivan Sergio Marcipar; Luis Fernando Calvinho; Maria Sol Barbagelata
Journal:  J Appl Genet       Date:  2018-05-03       Impact factor: 3.240

9.  Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.

Authors:  M B Marques; D L Kasper; A Shroff; F Michon; H J Jennings; M R Wessels
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Structural and biological characterization of a capsular polysaccharide produced by Staphylococcus haemolyticus.

Authors:  Sigrid Flahaut; Evgeny Vinogradov; Kathryn A Kelley; Shannon Brennan; Keiichi Hiramatsu; Jean C Lee
Journal:  J Bacteriol       Date:  2007-12-28       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.